UAE Diabetes Drugs Market Analysis Report [2022-30]

UAE Diabetes Drugs Market Analysis

$ 3999

The UAE diabetes drugs market size was valued at $308.97 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.1% from 2022 to 2030 and will reach $535 Mn in 2030. The market is segmented by drug type, application, and distribution channel. The UAE diabetes drug market will grow as the UAE government's initiatives to address the diabetes epidemic. The key market players are Neopharma (UAE), Julphar (Gulf Pharmaceutical Industries), Boehringer Ingelheim, and others.

ID: IN10AEPH009 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Chandani Patel

Buy Now

UAE Diabetes Drugs Market Executive Summary

The UAE diabetes drugs market size was valued at $308.97 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.1% from 2022 to 2030 and will reach $535 Mn in 2030. The United Arab Emirates (UAE) has been investing significantly in healthcare, with the aim of providing high-quality healthcare services to its citizens and residents. According to the World Health Organization (WHO), the UAE's total healthcare expenditure was estimated at 4.7% of its gross domestic product (GDP) in 2019. In 2019, the UAE's total healthcare expenditure was around $18 Bn. The government is the largest spender on healthcare in the UAE, accounting for approximately 73% of the total healthcare expenditure. The remaining 27% is spent by the private sector. The UAE's healthcare expenditure has been steadily increasing in recent years, reflecting the government's commitment to improving the healthcare system. The WHO reports that between 2010 and 2019, the UAE's healthcare expenditure increased by 56%. The government has also implemented various initiatives to improve healthcare access and affordability, such as providing free or subsidized healthcare to Emirati citizens and investing in telemedicine and digital health.

According to the International Diabetes Federation's Diabetes Atlas 2021, the prevalence of diabetes in the United Arab Emirates (UAE) in adults aged 20-79 years was 17.9% in 2021. This means that approximately 1.2 Mn adults in the UAE have diabetes. IDF estimates that the number of people with diabetes in the UAE is expected to increase to 2.05 Mn by 2045, representing a 72.2% increase from the 2021 estimates. The high prevalence of diabetes in the UAE is attributed to various factors such as a sedentary lifestyle, unhealthy diet, high rates of obesity, genetic factors, and an aging population. The government of the UAE has implemented various measures to address the problem, including increasing awareness, promoting healthy lifestyles, and providing free screening and treatment for diabetes. The high prevalence of diabetes in the UAE has a significant impact on the diabetes drugs market in the country. With such a large number of people affected by the disease, there is a high demand for diabetes drugs and related products.

The market for diabetes drugs in the UAE is growing, and it is expected to continue to grow in the coming years. Additionally, the growing adoption of advanced diabetes treatments such as insulin pumps, continuous glucose monitoring systems, and smart insulin pens is also contributing to the growth of the diabetes drugs market in the UAE. Increasing diabetes incidence in the UAE is driving the demand for diabetes drugs, and the market is expected to continue to grow in the coming years. The UAE government's initiatives to address the diabetes epidemic and the growing adoption of advanced diabetes treatments are expected to further boost the growth of the diabetes drugs market in the country.

uae diabetes drugs market

Market Dynamics

Market Growth Drivers Analysis

The diabetes drugs market in the UAE is driven by several factors. One of the key drivers is the high prevalence of diabetes in the country, which creates a high demand for diabetes drugs and related products. The UAE has one of the highest rates of diabetes in the world, with around 1.2 Mn adults estimated to have the disease. This has resulted in a significant market for diabetes drugs, as patients require medication to manage their condition.

Moreover, the UAE government's initiatives to address the diabetes epidemic. The UAE government has implemented various measures to increase awareness about diabetes and promote healthy lifestyles, including free screening and treatment for diabetes. These initiatives have led to increased demand for diabetes drugs as more people are diagnosed with the disease and require treatment.

In addition, the growing adoption of advanced diabetes treatments such as insulin pumps, continuous glucose monitoring systems, and smart insulin pens is driving the growth of the diabetes drug market in the UAE. Patients are increasingly opting for these advanced treatments, which offer improved accuracy and convenience compared to traditional methods.

Market Restraints

One of the major restraints is the high cost of diabetes drugs, which may limit access for some patients. In addition, the availability of cheaper generic alternatives could also pose a challenge for companies operating in the diabetes drugs market.

Competitive Landscape

Key Players

Neopharma (UAE)
Julphar (Gulf Pharmaceutical Industries)
Boehringer Ingelheim
Sanofi
Boehringer Ingelheim
Eli Lilly and Company
AstraZeneca
Johnson & Johnson
Bayer Pharmaceuticals
Novo Nordisk
Merck
Novartis
GlaxoSmithKline

Notable deals

January 2021: Julphar announced that it had entered into a partnership with the Abu Dhabi Stem Cell Center (ADSCC) to develop stem cell-based therapies for diabetes and other chronic diseases. The partnership aims to leverage Julphar's expertise in drug development and ADSCC's stem cell research capabilities to develop new treatments for diabetes.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

The UAE has a robust regulatory framework for pharmaceutical products, including diabetes drugs. The Ministry of Health and Prevention (MoHAP) is the primary regulatory body responsible for ensuring the safety, efficacy, and quality of pharmaceutical products in the UAE. All pharmaceutical products, including diabetes drugs, must be registered with the MoHAP before they can be sold in the UAE. The registration process involves a thorough review of the product's safety and efficacy data, as well as its manufacturing processes.

In addition, the MoHAP has established guidelines for the import and distribution of pharmaceutical products, including diabetes drugs. These guidelines outline the requirements for the storage, transport, and handling of pharmaceutical products, to ensure that they maintain their quality and efficacy throughout the supply chain. In the UAE, the government provides healthcare coverage to its citizens and residents through the mandatory health insurance scheme. Under this scheme, individuals and employers are required to purchase health insurance coverage for themselves and their employees.

Diabetes drugs are covered by health insurance in the UAE, but the coverage and reimbursement rates may vary depending on the type of insurance plan and the specific drugs prescribed. In general, health insurance plans in the UAE cover the cost of diabetes drugs as part of the overall treatment for diabetes.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Drugs Market Segmentation

By Drug Type (Revenue, USD Bn):

The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :

Injectable Drugs
- Insulin Based Injectables
- Non-insulin Based Injectables
  - Exenatide (Byetta)
  - Dulaglutide (Trulicity)
  - Semaglutide (Ozempic, Wegovy)
  - Liraglutide (`Saxenda, Victoza)
  - Lixisenatide (Adlyxin)
  - Pramlintide (Symlin)
  - Tirzepatide (Mounjaro)
  - Albiglutide (Tanzeum)
Oral Drugs
- Biguanides - Metformin (Glucophage and Glucophase XR)
- Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
- Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
- Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
- Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
- Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
- Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
- Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
- Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
- Others (Fixed Dose Combination Drugs)

By Application (Revenue, USD Bn):

Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.

Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
Other diabetes types

By Distribution Channel (Revenue, USD Bn):

Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.